Medicament for infantile autism caused by hypoxic-ischemic brain injury and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for hypoxia-ischemia and brain injury, which can be applied to medical formulas, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as insignificant efficacy of brain injury functions
Active Publication Date: 2021-09-14
广东康盾高新技术产业集团股份公司
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] Aiming at the occurrence matrix of hypoxic-ischemic brain injury, the corresponding drugs can alleviate or block the energy failure of brain cells and free radical damage. A composition that maintains glutamate transporter GLT-1 on the astrocyte membrane and reduces extracellular glutamate concentration during injury, but has no significant functional effect on brain injury
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0021] A medicament for children with autism caused by hypoxic-ischemic brain injury, comprising the following raw materials in parts by weight: 20 parts of ganoderma acid derivatives, 18 parts of total triterpenes of ganoderma lucidum, 26 parts of ligustrazine hydrochloride, 22 parts of bilobalide, 10 parts of teretin B, 12 parts of luteolin, 3 parts of pyridoxine.
Embodiment 2
[0023] A medicament for children with autism caused by hypoxic-ischemic brain injury, comprising the following raw materials in parts by weight: 50 parts of ganoderma acid derivatives, 45 parts of total triterpenes of ganoderma lucidum, 30 parts of ligustrazine hydrochloride, 34 parts of bilobalide, 20 parts of teretin B, 22 parts of luteolin, 15 parts of pyridoxine.
Embodiment 3
[0025] A medicament for children with autism caused by hypoxic-ischemic brain injury, comprising the following raw materials in parts by weight: 30 parts of ganoderma acid derivatives, 35 parts of total triterpenoids of ganoderma lucidum, 28 parts of ligustrazine hydrochloride, 28 parts of bilobalide, 15 parts of luteolin, 17 parts of luteolin, and 10 parts of pyridoxine.
[0026] The raw materials in parts by weight of the above-mentioned embodiments 1-3 are prepared by the following preparation method:
[0027] Step (1): dissolving ligustrazine hydrochloride, bilobalide, teretin, and luteolin in ethanol with a mass fraction of 85%, mixing and stirring to prepare a suspension with a drug concentration of 150 mg / mL;
[0028] Step (2): Dissolving ganoderma acid derivatives, ganoderma total triterpenes, and pyridoxine in water, stirring evenly, the stirring rate is 400 rpm, and the stirring time is 100 s;
[0029] Step (3): Mix steps (1) and (2), add 3 times the volume of water...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a medicament for infantile autism caused by hypoxic-ischemic brain injury and a preparation method thereof. The medicament comprises the following raw materials in parts by weight: 20-50 parts of ganoderic acid derivatives, 18-45 parts of ganoderma total triterpenes, 26-30 parts of ligustrazine hydrochloride, 22-34 parts of bilobalide, 10-20 parts of aesculetin, 12-22 parts of galuteolin and 3-15 parts of pyridoxine. The medicament provided by the invention has the advantages that the raw materials are reasonably selected and scientifically proportioned, the medicament has an obvious effect on infantile autism caused by hypoxic-ischemic brain injury, and the raw materials are combined to promote glucose and amino acid metabolism in the brain, increase the carotid artery blood flow, improve the cerebral blood flow and protect nerve cells from being damaged by various ischemia and neurotoxins.
Description
technical field [0001] The invention relates to the field of medicine preparation, in particular to a medicament for children with autism caused by hypoxic-ischemic brain injury and a preparation method thereof. Background technique [0002] Children's autism is a subtype of pervasive developmental disorder, with onset before the age of 3, characterized by qualitative impairment of social communication ability, language development disorder, rigid behavior and narrow interests, etc. It is a kind of disease. According to statistics in my country, about 61% of children with autism have mental retardation. It can be seen that most individuals with autism belong to the low-function category; while in high-function autism, the verbal IQ (VIQ ) and operational intelligence quotient (PIQ) test scores are also lower than normal children, which shows that the overall cognitive ability and learning ability of autistic children are poor. The causes of autism are mainly related to geneti...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more